ZA201807585B - Combination therapy with notch and pd-1 or pd-l1 inhibitors - Google Patents
Combination therapy with notch and pd-1 or pd-l1 inhibitorsInfo
- Publication number
- ZA201807585B ZA201807585B ZA2018/07585A ZA201807585A ZA201807585B ZA 201807585 B ZA201807585 B ZA 201807585B ZA 2018/07585 A ZA2018/07585 A ZA 2018/07585A ZA 201807585 A ZA201807585 A ZA 201807585A ZA 201807585 B ZA201807585 B ZA 201807585B
- Authority
- ZA
- South Africa
- Prior art keywords
- cancer
- lymphoblastic leukemia
- oxo
- carcinoma
- treating
- Prior art date
Links
- 239000012271 PD-L1 inhibitor Substances 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 229940121656 pd-l1 inhibitor Drugs 0.000 title abstract 2
- 239000012270 PD-1 inhibitor Substances 0.000 title 1
- 239000012668 PD-1-inhibitor Substances 0.000 title 1
- 229940121655 pd-1 inhibitor Drugs 0.000 title 1
- 208000006990 cholangiocarcinoma Diseases 0.000 abstract 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 abstract 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 241000288575 Astomaea Species 0.000 abstract 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010008342 Cervix carcinoma Diseases 0.000 abstract 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 206010059352 Desmoid tumour Diseases 0.000 abstract 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 abstract 1
- 208000036566 Erythroleukaemia Diseases 0.000 abstract 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 abstract 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 206010039491 Sarcoma Diseases 0.000 abstract 1
- 208000000453 Skin Neoplasms Diseases 0.000 abstract 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 abstract 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 abstract 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 abstract 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 abstract 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract 1
- 208000021841 acute erythroid leukemia Diseases 0.000 abstract 1
- 208000002517 adenoid cystic carcinoma Diseases 0.000 abstract 1
- 229960003852 atezolizumab Drugs 0.000 abstract 1
- 229950002916 avelumab Drugs 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010881 cervical cancer Diseases 0.000 abstract 1
- 201000006827 desmoid tumor Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229950009791 durvalumab Drugs 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 201000010536 head and neck cancer Diseases 0.000 abstract 1
- 208000014829 head and neck neoplasm Diseases 0.000 abstract 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 abstract 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 abstract 1
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229960003301 nivolumab Drugs 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 229960002621 pembrolizumab Drugs 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000849 skin cancer Diseases 0.000 abstract 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 abstract 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662339363P | 2016-05-20 | 2016-05-20 | |
| PCT/US2017/032790 WO2017200969A1 (en) | 2016-05-20 | 2017-05-16 | Combination therapy with notch and pd-1 or pd-l1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201807585B true ZA201807585B (en) | 2024-09-25 |
Family
ID=58772978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2018/07585A ZA201807585B (en) | 2016-05-20 | 2018-11-12 | Combination therapy with notch and pd-1 or pd-l1 inhibitors |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10688104B2 (OSRAM) |
| EP (1) | EP3458091B1 (OSRAM) |
| JP (1) | JP7194022B2 (OSRAM) |
| KR (1) | KR102463617B1 (OSRAM) |
| CN (2) | CN115845070A (OSRAM) |
| AU (1) | AU2017268187A1 (OSRAM) |
| BR (1) | BR112018073673A2 (OSRAM) |
| CA (1) | CA3025024A1 (OSRAM) |
| ES (1) | ES2904880T3 (OSRAM) |
| IL (1) | IL263110B (OSRAM) |
| MA (1) | MA45025A (OSRAM) |
| MX (1) | MX2018013941A (OSRAM) |
| SG (1) | SG11201810268YA (OSRAM) |
| WO (1) | WO2017200969A1 (OSRAM) |
| ZA (1) | ZA201807585B (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| BR112018000768A2 (pt) | 2015-07-13 | 2018-09-25 | Cytomx Therapeutics Inc | anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos |
| WO2017180385A1 (en) | 2016-04-12 | 2017-10-19 | Eli Lilly And Company | Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer |
| ES2881801T3 (es) | 2016-04-12 | 2021-11-30 | Lilly Co Eli | Terapia de combinación con inhibidores de Notch y CDK4/6 para su uso en el tratamiento de cáncer de pulmón |
| CA3025024A1 (en) | 2016-05-20 | 2017-11-23 | Eli Lilly And Company | Combination therapy with notch and pd-1 or pd-l1 inhibitors |
| US11376259B2 (en) | 2016-10-12 | 2022-07-05 | Eli Lilly And Company | Targeted treatment of mature T-cell lymphoma |
| WO2018151836A1 (en) | 2017-02-17 | 2018-08-23 | Fred Hutchinson Cancer Research Center | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
| SG11202003427XA (en) | 2017-11-06 | 2020-05-28 | Juno Therapeutics Inc | Combination of a cell therapy and a gamma secretase inhibitor |
| EP3823669A1 (en) * | 2017-12-18 | 2021-05-26 | Debiopharm International SA | Combination of an agonist anti-pd-1 antibody with a gnrh agonist or antagonist to treat cancer |
| US20220370397A1 (en) * | 2019-10-28 | 2022-11-24 | Enzychem Lifesciences Corporation | Methods and compositions for treatment of cancer |
| KR20240004519A (ko) * | 2021-04-28 | 2024-01-11 | 아센타위츠 파마슈티컬즈 리미티드 | 면역관문 억제제와 함께 akr1c3-활성화 화합물을 사용하는 병용 요법 |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3812952B2 (ja) | 1996-12-23 | 2006-08-23 | エラン ファーマシューティカルズ，インコーポレイテッド | シクロアルキル、ラクタム、ラクトンおよびその関連化合物およびその医薬組成物、並びに該化合物を用いたβ−アミロイドペプチドの放出および／またはその合成を阻害する方法 |
| AU768269B2 (en) | 1998-10-02 | 2003-12-04 | Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The | Apoptosis inducing agents and methods |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| GB0303663D0 (en) * | 2003-02-18 | 2003-03-19 | Lorantis Ltd | Assays and medical treatments |
| EP2418278A3 (en) | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| KR101607288B1 (ko) * | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| US7706658B2 (en) | 2005-07-05 | 2010-04-27 | Fujifilm Corporation | Copolymer and polymerizable composition |
| DE102006002966A1 (de) * | 2006-01-21 | 2007-07-26 | Schaeffler Kg | Laufscheibe mit integrierter Wälzkörperlaufbahn |
| US8633179B2 (en) | 2007-03-13 | 2014-01-21 | The Trustees Of Columbia University In The City Of New York | Synergistic interaction of NOTCH-1 inhibitors with glucocorticoids |
| EA017865B1 (ru) | 2007-03-28 | 2013-03-29 | Фармасайкликс, Инк. | Ингибиторы тирозинкиназы брутона |
| EP2535354B1 (en) | 2007-06-18 | 2017-01-11 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| US8188069B2 (en) | 2007-08-14 | 2012-05-29 | Eli Lilly And Company | Azepine derivatives as gamma-secretase inhibitors |
| BRPI0906831A2 (pt) | 2008-01-11 | 2019-09-24 | Hoffmann La Roche | uso de um inibidor de gama-secretase para tratamento de câncer |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EA023148B1 (ru) | 2008-08-25 | 2016-04-29 | Эмплиммьюн, Инк. | Композиции на основе антагонистов pd-1 и их применение |
| TWI729512B (zh) | 2008-12-09 | 2021-06-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| JO2885B1 (en) | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
| EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| EP2470054B1 (de) | 2009-08-26 | 2013-12-04 | FrXsh AG | Vorrichtung und verfahren zum mischen von mischgut |
| WO2011060051A1 (en) | 2009-11-12 | 2011-05-19 | University Of Massachusetts | Methods for treating glioblastoma |
| CN104961829B (zh) | 2009-11-24 | 2018-08-21 | 米迪缪尼有限公司 | 针对b7-h1的靶向结合剂 |
| CN102085372A (zh) | 2009-12-04 | 2011-06-08 | 中国医学科学院基础医学研究所 | Notch通路抑制剂用于治疗mTOR活化导致的肿瘤的用途 |
| JP2013532153A (ja) * | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体 |
| JO3003B1 (ar) | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
| AR087107A1 (es) * | 2011-07-27 | 2014-02-12 | Lilly Co Eli | Compuesto inhibidor de la señalizacion de la trayectoria notch |
| BR122022000334B1 (pt) * | 2011-08-01 | 2023-03-21 | Genentech, Inc | Composição farmacêutica compreendendo um antagonista de ligação ao eixo pd-1 e um inibidor de mek |
| KR101981873B1 (ko) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| WO2014193898A1 (en) * | 2013-05-31 | 2014-12-04 | Merck Sharp & Dohme Corp. | Combination therapies for cancer |
| US9698876B2 (en) | 2013-07-23 | 2017-07-04 | Telefonaktiebolaget Lm Ericsson (Publ) | Transmission mode allocation in LTE networks |
| ES2827679T3 (es) * | 2013-08-20 | 2021-05-24 | Merck Sharp & Dohme | Tratamiento del cáncer con una combinación de un antagonista de PD-1 y dinaciclib |
| GB201317929D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| WO2015117164A1 (en) * | 2014-02-03 | 2015-08-06 | Memorial Sloan-Kettering Cancer Center | Tumor-associated macrophages and methods and compositions for targeting cancer therapy and identifying potential responders |
| US10092645B2 (en) * | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| CN106488775A (zh) | 2014-07-11 | 2017-03-08 | 基因泰克公司 | Notch途径抑制 |
| JP7054622B2 (ja) | 2014-07-21 | 2022-04-14 | ノバルティス アーゲー | ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置 |
| US9465158B2 (en) * | 2014-09-04 | 2016-10-11 | National Taiwan Normal University | Light-guide coupler for modulating angular and spatial distributions of light source |
| KR20170060042A (ko) * | 2014-09-13 | 2017-05-31 | 노파르티스 아게 | Alk 억제제의 조합 요법 |
| BR112017008710A8 (pt) * | 2014-10-27 | 2023-04-25 | Hutchinson Fred Cancer Res | Composições e métodos para estimular a eficácia de imunoterapia celular adotiva |
| JP6827415B2 (ja) * | 2014-10-31 | 2021-02-10 | メレオ バイオファーマ ５ インコーポレイテッド | 疾患の処置のための併用療法 |
| HUE053995T2 (hu) | 2014-12-05 | 2021-08-30 | Memorial Sloan Kettering Cancer Center | B-sejt-érési antigént célzó antitestek és alkalmazási eljárások |
| US20180140602A1 (en) | 2015-04-07 | 2018-05-24 | Novartis Ag | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| CN108025001A (zh) | 2015-07-24 | 2018-05-11 | 安可初克公司 | 用于治疗免疫系统功能障碍的γ分泌酶调节剂 |
| ES2881801T3 (es) | 2016-04-12 | 2021-11-30 | Lilly Co Eli | Terapia de combinación con inhibidores de Notch y CDK4/6 para su uso en el tratamiento de cáncer de pulmón |
| WO2017180385A1 (en) | 2016-04-12 | 2017-10-19 | Eli Lilly And Company | Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer |
| CA3025024A1 (en) | 2016-05-20 | 2017-11-23 | Eli Lilly And Company | Combination therapy with notch and pd-1 or pd-l1 inhibitors |
| KR102512899B1 (ko) | 2016-08-31 | 2023-03-23 | 일라이 릴리 앤드 캄파니 | 고형 종양의 치료를 위한 투약 요법 |
| US11376259B2 (en) | 2016-10-12 | 2022-07-05 | Eli Lilly And Company | Targeted treatment of mature T-cell lymphoma |
| WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| SG11202003427XA (en) | 2017-11-06 | 2020-05-28 | Juno Therapeutics Inc | Combination of a cell therapy and a gamma secretase inhibitor |
-
2017
- 2017-05-16 CA CA3025024A patent/CA3025024A1/en active Pending
- 2017-05-16 SG SG11201810268YA patent/SG11201810268YA/en unknown
- 2017-05-16 AU AU2017268187A patent/AU2017268187A1/en not_active Abandoned
- 2017-05-16 CN CN202211692364.1A patent/CN115845070A/zh active Pending
- 2017-05-16 US US16/301,360 patent/US10688104B2/en active Active
- 2017-05-16 MX MX2018013941A patent/MX2018013941A/es unknown
- 2017-05-16 MA MA045025A patent/MA45025A/fr unknown
- 2017-05-16 WO PCT/US2017/032790 patent/WO2017200969A1/en not_active Ceased
- 2017-05-16 IL IL263110A patent/IL263110B/en unknown
- 2017-05-16 EP EP17726073.4A patent/EP3458091B1/en active Active
- 2017-05-16 BR BR112018073673-2A patent/BR112018073673A2/pt unknown
- 2017-05-16 JP JP2018560759A patent/JP7194022B2/ja active Active
- 2017-05-16 ES ES17726073T patent/ES2904880T3/es active Active
- 2017-05-16 KR KR1020187036486A patent/KR102463617B1/ko active Active
- 2017-05-16 CN CN201780044786.9A patent/CN109475629A/zh active Pending
-
2018
- 2018-11-12 ZA ZA2018/07585A patent/ZA201807585B/en unknown
-
2020
- 2020-05-08 US US16/870,853 patent/US11826317B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MA45025A (fr) | 2019-03-27 |
| IL263110B (en) | 2022-07-01 |
| ES2904880T3 (es) | 2022-04-06 |
| US11826317B2 (en) | 2023-11-28 |
| BR112018073673A2 (pt) | 2019-02-26 |
| CN109475629A (zh) | 2019-03-15 |
| KR102463617B1 (ko) | 2022-11-03 |
| US20190192531A1 (en) | 2019-06-27 |
| SG11201810268YA (en) | 2018-12-28 |
| CN115845070A (zh) | 2023-03-28 |
| US20220008432A1 (en) | 2022-01-13 |
| KR20190008913A (ko) | 2019-01-25 |
| WO2017200969A1 (en) | 2017-11-23 |
| AU2017268187A1 (en) | 2018-11-29 |
| US10688104B2 (en) | 2020-06-23 |
| EP3458091A1 (en) | 2019-03-27 |
| JP7194022B2 (ja) | 2022-12-21 |
| CA3025024A1 (en) | 2017-11-23 |
| JP2019516733A (ja) | 2019-06-20 |
| IL263110A (en) | 2018-12-31 |
| EP3458091B1 (en) | 2021-11-17 |
| MX2018013941A (es) | 2019-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201807585B (en) | Combination therapy with notch and pd-1 or pd-l1 inhibitors | |
| ZA202309638B (en) | Pyrimidine-fused cyclic compound, preparation method therefor and use thereof | |
| PH12020500066A1 (en) | Carboxamides as modulators of sodium channels | |
| JP2019516733A5 (OSRAM) | ||
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| MX380779B (es) | Terapia combinatoria con inhibidores notch y cdk4/6 | |
| RU2018102078A (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| MX2018012456A (es) | Terapia combinatoria con inhibidores notch y pi3k/mtor. | |
| MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
| MX2016008362A (es) | Combinaciones farmaceuticas. | |
| IN2014DN11099A (OSRAM) | ||
| BR112018002941A2 (pt) | métodos para tratar câncer pancreático metastático usando terapias de combinação compreendendo irinotecano lipossomal e oxaliplatina | |
| MX2020008395A (es) | Osimertinib para su uso en el tratamiento de cáncer de pulmón de células no pequeñas. | |
| MX2022009612A (es) | Combinacion de bi853520 con farmacos quimioterapeuticos. | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| MX2019002121A (es) | Tratamiento conjunto para tratar el cancer de pancreas. | |
| MX2021007477A (es) | Terapia de combinacion con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cancer. | |
| PH12021553177A1 (en) | Pharmaceutical composition for treating tumor | |
| UA103791C2 (uk) | Композиція, що включає модулятор pde4, і спосіб її застосування для лікування, профілактики або супроводу туберкульозу | |
| MX2022006566A (es) | Tratamientos conjuntos para tratamiento de cancer de mama. | |
| NZ596226A (en) | Antitumor combination including cabazitaxel and capecitabine | |
| PH12018502360A1 (en) | 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers | |
| EP4445914A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUMORS AND USE | |
| MX2014002817A (es) | Suspension oral. | |
| JP2011500723A5 (OSRAM) |